Picture of Conmed logo

CNMD Conmed News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid CapNeutral

Medical device maker Conmed raises 2026 organic rev outlook, reaffirms EPS guidance

Overview

U.S. medical device maker's Q1 sales fell 1.3% but beat analyst expectations

Adjusted EPS for Q1 declined yr/yr but beat analyst expectations

Company raised full-year 2026 organic revenue growth outlook to 5.0%-6.5%

Outlook

Conmed raises 2026 organic constant currency revenue growth outlook to 5.0%-6.5%

Company sees 2026 reported revenue at $1.350 bln-$1.375 bln, up from prior $1.345 bln-$1.375 bln

Conmed maintains 2026 adjusted diluted EPS guidance at $4.30-$4.45

Result Drivers

GI PRODUCT EXIT - Co said Q1 sales were reduced by $15.5 mln due to exit of certain gastroenterology products

STRATEGIC FOCUS - Co said it is concentrating resources and investment on higher-growth, higher-margin areas: minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair

Company press release: ID:nBw6bHbvda

Key Details

MetricBeat/MissActualConsensus Estimate
Q1 SalesBeat$317.05 mln$310.51 mln (6 Analysts)
Q1 Adjusted EPSBeat$0.89$0.82 (6 Analysts)
Q1 EPS$0.45
Q1 Net Income$13.83 mln
Q1 Income from Operations$25.42 mln
Q1 Pretax Profit$18.36 mln
Analyst Coverage The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell" The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy." Wall Street's median 12-month price target for Conmed Corp is $43.00, about 16.9% above its April 28 closing price of $36.79 The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 9 three months ago For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Conmed

See all news